Loading page
Loading page
Loading substance route
Oral bioavailability decreases significantly with dose due to saturation of the LAT1 transport system; administering lower doses more frequently (every 30-45 minutes) reduces wasted drug compared to larger single doses. Tolerance to anxiolytic effects develops with continuous use and returns to baseline 7-14 days after cessation.
Effects vary widely by individual, dose, and context.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Gabapentin is not considered psychologically addictive and demonstrates limited to no rewarding effects in human and animal experiments. Compulsive drug-seeking behavior and strong cravings are generally not observed, unlike with opioids, alcohol, or benzodiazepines. However, misuse does occur, particularly among individuals with a history of opioid or sedative abuse who may use it to boost opioid effects or manage withdrawal symptoms.
Physical dependence develops with chronic use, with withdrawal symptoms typically emerging 1-2 days after abrupt cessation and potentially lasting up to 45 days. Withdrawal symptoms are similar to, though generally less intense than, benzodiazepine withdrawal and include agitation, confusion, disorientation, gastrointestinal complaints, sweating, and less commonly tremor, tachycardia, hypertension, and insomnia. Withdrawal seizures have been reported following chronic use without periodic breaks. Gradual tapering is recommended.
Gabapentin has a wide therapeutic index with low acute toxicity. The oral TDLo (lowest published toxic dose) in humans is 2.86 mg/kg. Oral doses exceeding 8000 mg/kg failed to cause fatal reactions in rats, indicating a very high lethal threshold. Overdose symptoms include drowsiness, sedation, blurred vision, slurred speech, uncontrollable jerking motions, and somnolence. Death is possible at very high amounts, with risk substantially increased when combined with alcohol, opioids, or other CNS depressants. Gabapentin can be removed by hemodialysis.
Prolonged gabapentinoid use exceeding one year has been associated with increased risk of cardiovascular events and thrombotic events including deep venous thrombosis and pulmonary thromboembolism; thrombotic risk may emerge as early as three months of use.
Rare cases of drug reaction with eosinophilia and systemic symptoms (DRESS), a potentially fatal multi-organ hypersensitivity reaction, have been reported with gabapentin use.
Gabapentin may accumulate in patients with renal impairment, potentially leading to increased toxicity due to diminished clearance rather than direct nephrotoxicity; careful dosing is required in those with kidney problems.
Sexual dysfunction including loss of libido, anorgasmia, and erectile dysfunction may occur in some patients during gabapentin use.
Serious breathing suppression may occur when gabapentin is taken by individuals with underlying lung conditions such as COPD, independent of combination with other substances.
Psychiatric and behavioral adverse effects including hallucinations and psychosis can occur but are rare, primarily affecting pediatric populations and individuals with preexisting psychiatric conditions. Milder neuropsychiatric symptoms including confusion, depression, mood instability, aggression, agitation, and behavioral disturbances may occur in up to 29% of gabapentin users, though most reactions are mild to moderate and dose-dependent. The FDA has issued warnings regarding increased risk of suicidal thoughts and behaviors; some studies suggest approximately 40% increased risk of suicide or suicide attempt compared to other anticonvulsants, particularly in patients with bipolar disorder or epilepsy, though conflicting data exists with some studies showing reduced suicide rates in certain populations.
Gabapentin is an anticonvulsant that reduces seizure activity during use. However, withdrawal seizures may occur in some cases following chronic or semi-chronic use when the drug is discontinued abruptly, particularly in the absence of periodic breaks during repeated consecutive use. Gradual tapering is recommended to minimize withdrawal seizure risk.
Gabapentin was conceived and synthesized at Goedecke AG, a Parke-Davis subsidiary located in Freiburg, Germany. The compound was designed as a structural analog of gamma-aminobutyric acid (GABA) with enhanced capacity to penetrate the blood-brain barrier. Initial synthesis occurred between 1974 and…
Regulated as a prescription medicine. Available through licensed healthcare providers and pharmacies with a valid prescription.
Listed in Anlage 1 of the Arzneimittelverschreibungsverordnung (AMVV), requiring a prescription for dispensing. Regulated as a prescription-only medicine rather than a controlled narcotic substance.
Available at larger pharmacies without prescription. Both branded formulations (Pfizer Neurontin) and generic versions are available for direct purchase.
Federally unscheduled under the Controlled Substances Act but available by prescription only. Possession without a prescription is not illegal at the federal level. Classified as a Schedule V controlled substance in Alabama, Kentucky, Michigan, North Dakota, Tennessee, Virginia, and West Virginia. Prescription drug monitoring programs are in effect in Connecticut, District of Columbia, Indiana, Kansas, Massachusetts, Minnesota, Nebraska, New Jersey, Ohio, Oregon, Utah, and Wyoming.
Available as a prescription medication with multiple branded and generic formulations approved for medical use.
Classified as a Category B pharmaceutical under Swiss pharmaceutical law, requiring a medical prescription for dispensing.
Controlled as a Class C substance in the United Kingdom and Northern Ireland effective April 1, 2019. Available only with a valid prescription.
15 sources cited
